AETIOLOGY AND TRANSMISSION
• Gonorrhoea (meaning 'flow of seed' in old greek) and its related clinical manifestations are caused by infection with the Gram-negative bacterium Neisseria gonorrhoeae;
• Infection predominantly involves the columnar epithelium of the urethra, endocervix, rectum, pharynx and conjunctivae. Although it usually remains localised to the initial sites of infection, it can ascend to the upper genital tract to cause pelvic inflammatory disease and epididymo-orchitis or disseminate as bacteraemia;
• Transmission is by direct inoculation of infected secretion from one mucosa to another, i.e., genital-genital, genital-anorectal, oro-genital or oro-anal contact or by mother-tochild transmission at birth;
• In 2008, the World Health Organization (WHO) estimated 106 million cases of gonorrhoea among adults globally, a similar global incidence to genital chlamydial infections. 1 In Europe, gonorrhoea is the second most common bacterial sexually transmitted infection (STI), i.e. after chlamydial infections. 2 However, the incidence in several countries is underestimated because of suboptimal diagnostics, case reporting and surveillance. There is considerable geographic variation in the distribution of gonorrhoea and infection is reported three times more frequently in men than women, 2 reflecting the significantly higher proportion of symptoms in men and the burden of infection in men who have sex with men (MSM). The highest incidence of gonorrhoea is in young adults (15 to 29 years) and, in many countries, there is a disproportionate burden of disease in ethnic minority groups and MSM. [1] [2] [3] [4] 
CLINICAL FEATURES
Symptoms and physical signs of gonorrhoea commonly reflect localised inflammation of infected mucosal surfaces in the genital tract.
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Symptoms
• In men, the predominant presentation is of acute urethritis with symptoms of urethral discharge (>80%) and dysuria (>50%), usually starting within 2-8 days of exposure.
Asymptomatic urethral infection is uncommon in men (less than 10% of urethral infections);
• In women, genital tract symptoms relate to endocervical and urethral infection and include increased or altered vaginal discharge (≤50%), lower abdominal pain (≤25%), dysuria (10-15%) and rarely intermenstrual bleeding or menorrhagia. Endocervical infection is commonly asymptomatic (≥50%);
• Rectal and pharyngeal infections are usually asymptomatic. 9, 10 Physical signs
• In men, the most common finding on examination is a mucopurulent urethral discharge, which may be accompanied by erythema of the urethral meatus;
• In women, examination may be normal or a mucopurulent discharge may be evident from the cervix, sometimes accompanied with hyperaemia and contact bleeding of the endocervix.
Complications
Pelvic inflammatory disease (PID) in women and epididymo-orchitis in men are the most notable complications from local spread of gonococcal infection.
Gonococcal bacteraemia rarely occurs (less than 1% of infections) and is usually manifested by skin lesions, fever, arthralgia, acute arthritis and tenosynovitis (disseminated gonococcal infection (DGI)).
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DIAGNOSIS
• The diagnosis of uncomplicated gonorrhoea is established by identification of N.
gonorrhoeae in genital, rectal, pharyngeal or ocular secretions;
• N. gonorrhoeae can be detected by nucleic acid amplification tests (NAATs) or culture.
The bacterium can also be visualized on microscopy of stained genital tract smear to facilitate rapid diagnosis in symptomatic patients. No test offers 100% sensitivity and specificity;
• Microscopy (×1000) using Gram or methylene blue staining for identification of diplococci within polymorphonuclear leukocytes offers good sensitivity (≥95%) and specificity as a rapid diagnostic test in symptomatic men with urethral discharge [level of evidence III; grade C recommendation]. 5, 6, 13 • NAATs are more sensitive than culture, offer testing on a wider range of specimen types and are less demanding in specimen quality, transportation and storage. [17] [18] [19] [20] [21] [22] [23] [24] [25] They show high sensitivity (>96%) in both symptomatic and asymptomatic infection, show equivalent sensitivity in urine and urethral swab specimens from men 23 and equivalent sensitivity in clinician-taken or self-taken vulvo-vaginal and endocervical swabs from women. 24 NAATs significantly outperform transported samples for culture and are the sample of choice for testing individuals who are asymptomatic. 17, 18 In women, urine samples offer a lower sensitivity than swabs from the genital tract and are not the optimal sample for testing [II; B]. 17, 20, 21, 25 The performance characteristics of different commercially available or in house gonococcal NAATs differ substantially, particularly in regard to specificity;
• When using NAATs to detect N. gonorrhoeae, the positive predictive value (PPV) of the testing protocol used should exceed 90%. The principal factors influencing the PPV are the prevalence of gonorrhoea in the population tested and variation in the specificity of [26] [27] [28] • NAATs are significantly more sensitive than culture for detecting pharyngeal and rectal infection [29] [30] [31] [32] [33] [34] [35] and are the test of choice for screening for rectal and pharyngeal gonococcal infection. However, commercially available NAATs are not licensed for testing specimens from these sites and they differ significantly in their specificity, 36, 37 particularly at the pharynx due to the frequent presence of non-gonococcal Neisseria • Women may have genital tract infection localized to the endocervix or urethra. In the current era of NAAT testing, asymptomatic women are commonly offered screening for gonorrhoea and chlamydial infection by a single vulvo-vaginal or endocervical test. 38 This pragmatic approach is endorsed although there remains a lack of evidence to confirm its effectiveness in excluding gonorrhoea [IV, C]. The additional contribution of routinely testing rectal and pharyngeal sites when screening women for gonorrhoea is poorly defined in Europe, although sampling these sites should be considered when there is a history of direct exposure [IV; C]. 10 Evidence on the minimum incubation period necessary before testing can be recommended is lacking, although clinical experience suggests that positive NAAT results may be observed within 1-2 days of infection.
• A minority of MSM with gonorrhoea (20-30%) have infection at multiple sites. 9, 39 Tests should be taken from the urethra/urine, rectum and pharynx as directed by sexual practices.
Indications for testing [IV; C]
• Symptoms or signs of urethral discharge in men;
• Vaginal discharge with risk factor for STI (age <30 years, new sexual partner);
• Mucopurulent cervicitis;
• Persons diagnosed with any other STI;
• Sexual partner of persons with an STI or PID;
• Acute epididymo-orchitis in a male aged <40 years;
• Acute pelvic inflammatory disease;
• When screening young adults (<25 years of age) for sexually transmitted infection;
• When screening individuals with new or multiple recent sexual partners;
• Purulent conjunctivitis in a neonate or adult;
• Mother of a newborn with ophthalmia neonatorum.
MANAGEMENT OF PATIENT
Information, explanation and advice for the patient • A patient information leaflet is available on the IUSTI -Europe website for guidelines (http://www.iusti.org/regions/Europe/euroguidelines.htm).
Therapy
Neisseria gonorrhoeae has shown a remarkable capacity to develop resistance to multiple classes of antibiotics including penicillins, tetracyclines, macrolides and fluoroquinolones. 40 
Indications for therapy [IV; C]
• Identification of intracellular diplococci at a genital site by Gram-stain or Methylene bluestain microscopy;
• Positive culture or confirmed NAAT from any site for N. gonorrhoeae (or unconfirmed NAAT from urogenital specimens in settings where PPV>90%);
• On epidemiological grounds, if a recent partner has confirmed gonococcal infection;
• On epidemiological grounds, mother of neonate with confirmed gonococcal infection;
• On epidemiological grounds, treatment can be considered following sexual assault;
• On demonstration of a purulent urethral discharge in men or mucopurulent cervicitis in women when rapid diagnostic tests are not available and after specimen collection for laboratory testing. In this circumstance, combined treatment for gonococcal and chlamydial infection should always be given.
Recommended treatments for uncomplicated N. gonorrhoeae infections of the urethra, cervix
and rectum in adults and adolescents when the antimicrobial sensitivity of the infection is unknown.
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Ceftriaxone 500 mg intramuscularly (IM) as a single dose together with azithromycin 2 g as single oral dose [IV; C].
NOTE: Azithromycin tablets may be taken with or without food but gastrointestinal side effects can be less if taken after food.
If ceftriaxone 500 mg for IM injection is not available, the IM suspension can be mixed as follows: 3.5 ml of 10 mg/ml lidocaine without adrenalin is suspended into a 1 gram vial of ceftriaxone and mixed. 2 ml of the mixture is drawn and injected IM. Co-infection with C. trachomatis is common in young (<30 years) heterosexual patients and MSM with gonorrhoea. 3 If treatment for gonorrhoea does not include azithromycin, treatment with azithromycin 1 g oral as a single dose or doxycycline 100 mg oral dose twice daily for 7 days should be given for possible chlamydial co-infection unless co-infection has been excluded with NAAT testing [GPP -good practice point].
Alternative regimens
57,58
• Other single dose cephalosporin regimens Cefixime 400 mg has been widely used as an oral single dose treatment for gonorrhoea.
Multiple recent reports of treatment failures and pharmacodynamic investigations have raised serious concerns over the adequacy of 400 mg of cefixime as single dose treatment. 42, [44] [45] [46] [47] 49 Cefixime is only an alternative option if administration of an intramuscular injection is not possible or refused by the patient. However, caution should be taken using cefixime 400 mg only, particularly for treatment of pharyngeal infection, and ideally, if used, it should always be given together with azithromycin 2 g as a single oral dose (see alternative regimen 1 above).
Alternative injectable or oral cephalosporins offer no advantage in terms of efficacy and pharmokinetics/pharmacodynamics over ceftriaxone or cefixime, and treatment efficacy for pharyngeal infection is less certain. Accordingly, alternative cephalosporins cannot be recommended.
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• Single dose fluoroquinolone regimens 
Therapy for uncomplicated gonococcal infection of the pharynx
Many antimicrobials have demonstrated lower efficacy (≤90%) in eradicating N. gonorrhoeae from the pharynx than in eradicating genital and anorectal infection. [56] [57] [58] [59] [60] 71, 72 This correlates with the pharmacokinetic properties of the individual antimicrobials. Treatment with spectinomycin has poor efficacy at eradicating pharyngeal gonorrhoea.
40,56-60
Recommended treatment for pharyngeal infection
Ceftriaxone 500 mg IM as a single dose together with azithromycin 2 g oral single dose [IV; C].
Alternative regimens
Ceftriaxone 500 mg IM as a single dose [IV; C]. This regimen is only an alternative option if azithromycin is not available or patient is unable to take oral medication.
Alternative treatments for pharyngeal infection when there is a history of penicillin anaphylaxis or cephalosporin allergy and fluoroquinolone or azithromycin resistance are excluded by appropriate laboratory susceptibility testing:
• Ciprofloxacin 500 mg as a single oral dose or ofloxacin 400 mg as a single oral dose or azithromycin 2 g as a single oral dose.
Therapy of genital, anorectal and pharyngeal gonococcal infection when extended-spectrum cephalosporin resistance identified
• Ceftriaxone 1 g IM as a single dose together with azithromycin 2 g oral single dose [IV, C].
• Gentamicin 240 mg IM as a single dose together with azithromycin 2 g oral as single dose [IV, C] . This combination is currently under clinical study and may be valuable if infection persists after treatment with ceftriaxone. 73, 74 Gentamicin has been successfully used in Malawi, Africa for many years (mainly in syndromic management administered together with doxycycline) 75 and high in-vitro susceptibility in Europe has been proven. 76 However, randomized, quality assured clinical trials need to confirm the efficacy of this treatment regimen.
Therapy of gonococcal infections in pregnancy or when breastfeeding
• Recommended treatment 77 Ceftriaxone 500 mg IM as a single dose [Ib; A].
Alternative regimen
Spectinomycin 2 g IM as a single dose (has poor efficacy for treatment of pharyngeal gonorrhoea). 40, [56] [57] [58] [59] [60] The safety of azithromycin in pregnancy has not been confirmed but clinical experience indicates that it may be safely used. It should only be used under medical supervision if the expected benefit to the mother is thought to be greater than the possible risk to the foetus. 78 Azithromycin passes into breast milk and is not recommended whilst breast feeding. Pregnant and breastfeeding women should not be treated with fluoroquinolone or tetracycline antimicrobials.
Therapy of gonococcal infections in patients with penicillin allergy
Third-generation cephalosporins show negligible cross-allergy with penicillins and allergy to these cephalosporins is rare. 79, 80 If allergy is not excluded and third-generation cephalosporins still need to be given, the patient should be under medical supervision for at least 30 minutes.
• Recommended treatment for patients with a history of penicillin anaphylaxis or 
Therapy for upper genital tract gonococcal infection
Gonococcal epididymo-orchitis
• Recommended treatments when gonorrhoea is diagnosed in a man with acute epididymoorchitis:
Ceftriaxone 500 mg IM as a single dose together with doxycycline 100 mg oral dose twice daily for 10-14 days [IV; C].
Ciprofloxacin 500 mg as a single oral dose may be used as an alternative to ceftriaxone when sensitivity confirmed by appropriate laboratory susceptibility testing.
(see also European Guideline on Epididymo-orchitis)
Gonococcal pelvic inflammatory disease
• Recommended treatments when gonorrhoea is the suspected/possible cause of PID:
Ceftriaxone 500 mg IM as a single dose together with doxycycline 100 mg oral dose twice daily together with metronidazole 400 mg oral dose twice daily for 14 days [IV; C].
(see also European Guideline on Pelvic Infection).
Therapy for disseminated gonococcal infection
There have been no clinical trials on the treatment of disseminated gonococcal infection (DGI)
since the progressive development of antimicrobial resistance by N. gonorrhoeae. Treatment is based on current antimicrobial sensitivity data, observational data from case series and the principals of treating septicaemia. Hospitalization is recommended for initial therapy. 11, 12, 57, 59, 81, 82 • Recommended treatment [IV; C]:
Initial therapy:
1. Ceftriaxone 1 g IM or IV every 24 hours.
Spectinomycin 2 g IM every 12 hours.
Therapy should continue for 7 days, but may be switched 24-48 hours after symptoms improve to one of the following oral regimens:
Cefixime 400 mg oral dose twice daily or if fluoroquinolone sensitivity is confirmed by appropriate laboratory susceptibility testing:
Ciprofloxacin 500 mg oral dose or ofloxacin 400 mg oral dose, twice daily.
Therapy for gonococcal conjunctivitis
A three day systemic regimen is recommended as the cornea may be involved and is relatively avascular [IV; C]. 57 The eye should be irrigated with sterile saline solution once.
• Ceftriaxone 500 mg IM as a single dose daily for 3 days.
• If history of penicillin anaphylaxis or cephalosporin allergy:
Spectinomycin 2 g IM as a single dose daily for 3 days.
Or, if antibiotic susceptibility testing at laboratory has excluded resistance:
Azithromycin 2 g oral as a single dose together with doxycycline 100 mg oral dose twice daily for 1 week together with ciprofloxacin 250 mg oral dose daily for 3 days [IV; C]
Therapy for ophthalmia neonatorum (gonococcal neonatal conjunctivitis) 58 The eye should be irrigated frequently with sterile saline solution.
• Ceftriaxone 25-50 mg/kg IV or IM as a single dose, not to exceed 125 mg
CONTACT TRACING AND MANAGEMENT OF SEX PARTNER(S)
• Sex partners should be contacted and offered testing together with treatment and counseling for gonorrhoea and chlamydial infection [IV; C];
• For cases of gonorrhoea, all sex partners within the preceding 60 days of onset of symptoms or diagnosis should be evaluated and treated [IV; C]. [57] [58] [59] [60] If a patient's last sexual contact was more than 60 days prior to their diagnosis, their last sexual partner should be evaluated.
FOLLOW UP AND TEST OF CURE
• Assessment after treatment is recommended to confirm compliance with therapy, resolution of symptoms and signs, exclude re-infection and ensure partner notification
• A test of cure is recommended in all cases to identify persisting infection and emerging resistance. 16 Test of cure is particularly important to perform to ensure effective eradication of pharyngeal infection, which is substantially harder to treat than genital and anorectal infections. [56] [57] [58] [59] [60] 71, 72 When symptoms persist after treatment, culture is recommended to identify persisting infection and for antimicrobial sensitivity testing and may be performed 3-7 days after completion of therapy, possibly supplemented a week later with a NAAT for increased sensitivity if culture is negative. Tests of cure in asymptomatic patients can be performed with a NAAT 2 weeks after completion of treatment and ideally, all positives should be cultured and antibiotic susceptibility testing performed before further treatment is given [IV; C]. 
QUALIFYING STATEMENT
Decisions to follow these recommendations must be based on professional clinical judgement, consideration of individual patient circumstances and available resources. All possible care has been undertaken to ensure publication of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing clinician to ensure the accuracy and appropriateness of the medication they prescribe.
EDITORIAL BOARD
Keith 
Ib
Evidence obtained from at least one randomised controlled trial.
IIa
Evidence obtained from at least one well designed study without randomisation.
IIb
Evidence obtained from at least one other type of well designed quasi-experimental study. were also reviewed.
